Search research articles
Contact Us
Filters
Showing results (261-270 of 403) with videos related to
Page
of 41
Sort By:
Bone Marrow Transplantation
|
February 6, 2019
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT
Giorgia Battipaglia, Ariane Boumendil, Myriam Labopin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2007
Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party
Christoph Schmid, Myriam Labopin, Arnon Nagler, et al.
American Journal of Hematology
|
February 5, 2010
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
Michael B Lilly, Oliver G Ottmann, Neil P Shah, et al.
Transplantation
|
May 7, 2014
Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
Olle Ringdén, Myriam Labopin, Martin Solders, et al.
The Lancet. Oncology
|
November 22, 2012
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
Norbert Schmitz, Maike Nickelsen, Marita Ziepert, et al.
Oncotarget
|
January 10, 2018
Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
Nicola Mitwasi, Anja Feldmann, Ralf Bergmann, et al.
Blood Cancer Journal
|
April 14, 2019
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
Frédéric Baron, Myriam Labopin, Annalisa Ruggeri, et al.
American Journal of Hematology
|
April 28, 2009
Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics
Crawford J Strunk, Uwe Platzbecker, Christian Thiede, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2009
Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup
Jürgen Krauter, Katharina Wagner, Irina Schäfer, et al.
Cytotherapy
|
January 10, 2015
Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease
Anke Theil, Sebastian Tuve, Uta Oelschlägel, et al.
Page
of 41
Search research articles
Search
Showing results (261-270 of 403) with videos related to
Sort By:
Page
of 41
Bone Marrow Transplantation
|
February 6, 2019
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT
Giorgia Battipaglia, Ariane Boumendil, Myriam Labopin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2007
Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party
Christoph Schmid, Myriam Labopin, Arnon Nagler, et al.
American Journal of Hematology
|
February 5, 2010
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
Michael B Lilly, Oliver G Ottmann, Neil P Shah, et al.
Transplantation
|
May 7, 2014
Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
Olle Ringdén, Myriam Labopin, Martin Solders, et al.
The Lancet. Oncology
|
November 22, 2012
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
Norbert Schmitz, Maike Nickelsen, Marita Ziepert, et al.
Oncotarget
|
January 10, 2018
Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
Nicola Mitwasi, Anja Feldmann, Ralf Bergmann, et al.
Blood Cancer Journal
|
April 14, 2019
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
Frédéric Baron, Myriam Labopin, Annalisa Ruggeri, et al.
American Journal of Hematology
|
April 28, 2009
Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics
Crawford J Strunk, Uwe Platzbecker, Christian Thiede, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2009
Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup
Jürgen Krauter, Katharina Wagner, Irina Schäfer, et al.
Cytotherapy
|
January 10, 2015
Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease
Anke Theil, Sebastian Tuve, Uta Oelschlägel, et al.
Page
of 41